Undervalued Stocks to Watch Now! $IPA.V / $IPA
Post# of 49
https://topnewsguide.com/2022/07/29/undervalu...ipa-v-ipa/
ImmunoPrecise Antibodies (NASDAQ: IPA) (TSXV: IPA) announced its financial results for the full year today. The total revenues for the fiscal year came in at $19.4 million, which worked out to a rise of 8.1% from the previous year. Moreover, it proved to be a record for IPA as well.
The company managed to bring in project revenues of $1.4 million and which worked out to be 9.1%. However, that was not all. It was also announced that IPA had also managed to make a strategic investment worth as much as $6.7 million through its subsidiary unit Talem Therapeutics LLC.